Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Earnings season continues, and we're here to spotlight the companies set to unveil their financial results in the next trading day, helping you prepare for the market action. Leading the charge are ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals (VRTX) closed the most recent trading day ... Meanwhile, the Dow gained 0.31%, and the Nasdaq, a tech-heavy index, added 2.03%. Heading into today, shares of the drugmaker ...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...
In trading on Friday, shares of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) crossed above their 200 day moving average of $458.68, changing hands as high as $469.00 per share. Vertex ...
CPI Readings Due in U.S. Next Week Monday U.S. Featured Earnings McDonalds (NYSE:MCD) (Q4) EPS of $2.82 compared to $2.95 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback